Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ExtracorporeaL life support and Modification Of Hemostasis: the ELMOH trial: hemostatic changes during the first 48 h of VV- and VA-ECMO: a prospective multicenter cohort study.

Critical care (London, England)·2026
Same author

Can prothrombin time assays withstand the influence of antiprothrombin and anti-β2-glycoprotein I antibodies on the international normalized ratio?

Research and practice in thrombosis and haemostasis·2026
Same author

"Effect of direct oral anticoagulants in cirrhosis: an in vitro study": comment.

Journal of thrombosis and haemostasis : JTH·2026
Same author

ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis.

Hepatology communications·2026
Same author

Erratum to '2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain-collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non-enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies': [Journal of Thrombosis and Haemostasis. Volume 23, Issue 1, January 2025, Pages 341-344].

Journal of thrombosis and haemostasis : JTH·2026
Same author

The influence of antiphospholipid antibodies on prothrombin time and international normalized ratio: a scoping review.

Critical reviews in clinical laboratory sciences·2025
Same journal

Gut Microbiome-Associated Thrombosis: Approaching Validation?

Seminars in thrombosis and hemostasis·2026
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Solid Phase Assays for Antiphospholipid Antibodies.

Katrien M J Devreese1

  • 1Department of Diagnostic Sciences, Coagulation Laboratory, Ghent University Hospital, Ghent University, Ghent, Belgium.

Seminars in Thrombosis and Hemostasis
|June 8, 2022
PubMed
Summary
This summary is machine-generated.

Diagnosing antiphospholipid syndrome (APS) requires detecting antiphospholipid antibodies (aPL). Solid phase assays for anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies are crucial but face standardization challenges.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.4K

Related Experiment Videos

Last Updated: Sep 20, 2025

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.4K

Area of Science:

  • Immunology
  • Clinical Chemistry

Background:

  • Antiphospholipid syndrome (APS) diagnosis depends on detecting antiphospholipid antibodies (aPL).
  • Current laboratory criteria include lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I (aβ2GPI) antibodies.
  • Solid phase assays for aCL and aβ2GPI are essential for aPL detection.

Purpose of the Study:

  • To address methodological challenges in aCL and aβ2GPI assays.
  • To improve understanding of the diagnostic role of these antibodies.
  • To highlight issues with inter-assay variability and semiquantitative classification.

Main Methods:

  • Review of guidelines for measuring aPL.
  • Analysis of diagnostic roles of aCL and aβ2GPI assays.
  • Discussion of non-criteria aPL, including anti-domain 1 β2GPI and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Main Results:

  • Solid phase assays for aCL and aβ2GPI exhibit significant inter-assay variability.
  • This variability leads to disagreements in positive/negative results and antibody titers.
  • Standardization remains a challenge for semiquantitative classification.

Conclusions:

  • Despite advancements, solid phase assays for aCL and aβ2GPI require further standardization.
  • Non-criteria aPL, such as anti-domain 1 β2GPI and aPS/PT, may aid in risk assessment for APS.
  • These additional antibodies are particularly useful in patients with incomplete diagnostic profiles.